JPWO2022081033A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022081033A5
JPWO2022081033A5 JP2023523099A JP2023523099A JPWO2022081033A5 JP WO2022081033 A5 JPWO2022081033 A5 JP WO2022081033A5 JP 2023523099 A JP2023523099 A JP 2023523099A JP 2023523099 A JP2023523099 A JP 2023523099A JP WO2022081033 A5 JPWO2022081033 A5 JP WO2022081033A5
Authority
JP
Japan
Prior art keywords
pharma
acceptable derivative
pharmaceutical
levodopa
pharmaceutical combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023523099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546140A5 (https=
JP2023546140A (ja
Publication date
Priority claimed from GBGB2016425.7A external-priority patent/GB202016425D0/en
Application filed filed Critical
Publication of JP2023546140A publication Critical patent/JP2023546140A/ja
Publication of JPWO2022081033A5 publication Critical patent/JPWO2022081033A5/ja
Publication of JP2023546140A5 publication Critical patent/JP2023546140A5/ja
Pending legal-status Critical Current

Links

JP2023523099A 2020-10-16 2021-10-14 パーキンソン病の治療のためのオピカポン及びレボドパ Pending JP2023546140A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2016425.7A GB202016425D0 (en) 2020-10-16 2020-10-16 Treatment regimens for parkinson's disease
GB2016425.7 2020-10-16
PCT/PT2021/050036 WO2022081033A1 (en) 2020-10-16 2021-10-14 Opicapone and levodopa for the treatment of parkinson's disease

Publications (3)

Publication Number Publication Date
JP2023546140A JP2023546140A (ja) 2023-11-01
JPWO2022081033A5 true JPWO2022081033A5 (https=) 2024-10-11
JP2023546140A5 JP2023546140A5 (https=) 2024-10-11

Family

ID=73598546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023523099A Pending JP2023546140A (ja) 2020-10-16 2021-10-14 パーキンソン病の治療のためのオピカポン及びレボドパ

Country Status (8)

Country Link
US (1) US20230398105A1 (https=)
EP (1) EP4228618A1 (https=)
JP (1) JP2023546140A (https=)
KR (1) KR20230088753A (https=)
CN (1) CN116490171A (https=)
AU (1) AU2021360114A1 (https=)
GB (1) GB202016425D0 (https=)
WO (1) WO2022081033A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860603A1 (en) 2018-10-05 2021-08-11 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
JP2024500754A (ja) * 2020-12-17 2024-01-10 ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ 早期特発性パーキンソン病のための治療レジメン
GB202212082D0 (en) * 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110002462A (ko) 2008-03-17 2011-01-07 바이알 - 포르텔라 앤드 씨에이 에스에이 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형
AU2010231961B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
RU2550133C2 (ru) 2009-04-01 2015-05-10 БИАЛ-ПОРТЕЛА энд КА., С.А. Фармацевтические составы, включающие производные нитрокатехола, и способы их получения
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2013089573A1 (en) 2011-12-13 2013-06-20 BIAL - PORTELA & Cª., S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
JP2018500300A (ja) * 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
RU2018110580A (ru) * 2015-08-27 2019-09-30 Прекстон Терапьютикс Са Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии
MX383906B (es) * 2015-10-09 2025-03-14 Teva Pharmaceuticals Int Gmbh Combinación de levodopa deuterado con carbidopa y opicapona para el tratamiento del mal de parkinson
JP2020023540A (ja) * 2019-10-11 2020-02-13 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬

Similar Documents

Publication Publication Date Title
US20230355560A1 (en) Medicaments for slowing parkinson's disease
JP2572768B2 (ja) レボドパメチルエステルを有効成分とするパ−キンソン病治療剤
JP2009511618A (ja) 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用
Factor et al. Emergency department presentations of patients with Parkinson's disease
CN101291663A (zh) 预防和治疗睡眠呼吸障碍的方法和工具
WO2006051154A1 (en) Treatment of restless legs syndrome
Khan Off spells and dyskinesias: pharmacologic management of motor complications
Poewe Clinical aspects of motor fluctuations in Parkinson's disease
KR20230088753A (ko) 파킨슨병 치료를 위한 오피카폰 및 레보도파
JP2016505050A5 (https=)
Moore et al. Management of Motor
JPWO2022081033A5 (https=)
Otto et al. The Use of Intravenous Glutathione for Symptom Management of Parkinson's Disease: A Case Report.
JP2021530568A5 (https=)
EP2709608B1 (en) Compositions for treating postural reflex abnormality caused by parkinson's disease
JP2014530249A5 (https=)
JPWO2022158992A5 (https=)
JPWO2023043999A5 (https=)
UA112652C2 (uk) Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції
Brydon et al. An update of opicapone in Parkinson’s disease: evidence-based results of recent trials
Dolhun et al. Levodopa 2.0: New Strategies to Even Out the Peaks and Valleys
Hardie Problems and unanswered questions concerning levodopa treatment in Parkinson's disease
CA2498639A1 (en) Niacin used as oral supplementation for the treatment and prevention of sexual dysfunction in human males and females
Vo et al. Guidelines for the Use of Parkinsonian Drugs (in USA)
Tse et al. Restless legs syndrome: differential diagnosis and treatment